Danaher Co. (NYSE:DHR) Shares Purchased by Delaney Dennis R

Delaney Dennis R boosted its stake in shares of Danaher Co. (NYSE:DHR) by 2.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,763 shares of the conglomerate’s stock after acquiring an additional 655 shares during the quarter. Danaher comprises 3.2% of Delaney Dennis R’s investment portfolio, making the stock its 17th biggest holding. Delaney Dennis R’s holdings in Danaher were worth $5,934,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Broderick Brian C lifted its position in Danaher by 4.4% during the 1st quarter. Broderick Brian C now owns 62,224 shares of the conglomerate’s stock worth $15,539,000 after acquiring an additional 2,633 shares during the period. Hemenway Trust Co LLC lifted its position in Danaher by 3.3% during the 1st quarter. Hemenway Trust Co LLC now owns 154,736 shares of the conglomerate’s stock worth $38,641,000 after acquiring an additional 4,881 shares during the period. Hemington Wealth Management acquired a new stake in Danaher during the 1st quarter worth approximately $216,000. Howland Capital Management LLC lifted its position in Danaher by 0.4% during the 1st quarter. Howland Capital Management LLC now owns 177,427 shares of the conglomerate’s stock worth $44,354,000 after acquiring an additional 662 shares during the period. Finally, Geneos Wealth Management Inc. lifted its position in Danaher by 3.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 14,272 shares of the conglomerate’s stock worth $3,564,000 after acquiring an additional 462 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Danaher news, CEO Rainer Blair sold 9,005 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the transaction, the chief executive officer now owns 106,990 shares of the company’s stock, valued at $28,352,350. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Rainer Blair sold 9,005 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the sale, the chief executive officer now owns 106,990 shares in the company, valued at $28,352,350. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Matthew Mcgrew sold 46,377 shares of the firm’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $253.05, for a total value of $11,735,699.85. Following the sale, the chief financial officer now owns 29,407 shares in the company, valued at approximately $7,441,441.35. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 148,783 shares of company stock valued at $37,536,717. Corporate insiders own 10.90% of the company’s stock.

Danaher Price Performance

Danaher stock traded up $4.07 during mid-day trading on Thursday, hitting $246.27. 2,793,164 shares of the company were exchanged, compared to its average volume of 2,861,634. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. The business’s 50 day simple moving average is $255.05 and its two-hundred day simple moving average is $247.31. The company has a market capitalization of $182.41 billion, a P/E ratio of 41.74, a PEG ratio of 3.68 and a beta of 0.83. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $269.11.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. Danaher’s revenue was down 2.6% compared to the same quarter last year. During the same quarter last year, the business posted $2.36 earnings per share. Analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date is Friday, June 28th. Danaher’s payout ratio is 18.31%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on DHR shares. Evercore ISI decreased their price objective on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Barclays increased their target price on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 24th. HSBC raised Danaher from a “hold” rating to a “buy” rating and increased their target price for the stock from $250.00 to $280.00 in a research note on Wednesday, April 17th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Finally, Jefferies Financial Group began coverage on Danaher in a research note on Monday, June 3rd. They set a “buy” rating and a $295.00 target price for the company. Six analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average target price of $268.67.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.